Devonian Health Group Inc. announced the appointment of Ms. Kathryn J. Gregory to the Board, effective February 28, 2024. Kathryn J. Gregory has over 25 years of executive leadership experience in startup, mid-sized and large pharmaceutical and biotechnology companies. She has extensive experience in international business development including corporate strategy, licensing, mergers and acquisitions, alliance management and operational expertise in marketing, strategic sourcing and procurement.

Ms. Gregory serves as Head of Business Development at Rgenta Therapeutics Inc., a small molecule ribonucleic acid modulation company, and concurrently as Chief Business Officer of reVision Therapeutics Inc., a startup ophthalmology company. Ms. Gregory currently serves as director of Carmell Corporation, a bio-aesthetics company focused on topical skin and hair care. Over her career, Ms. Gregory has led global business development functions for several pharmaceutical companies of all sizes.

She received an M.B.A. from Pepperdine University and a B.A. degree from the University of California, Berkeley.